<DOC>
	<DOCNO>NCT00150904</DOCNO>
	<brief_summary>Hepatitis C HIV infect worldwide million people lead high rate coinfected patient eventually liver cirrhosis endstage liver disease . With currently best available therapy ( peginterferon ribavirin ) less 50 % patient HCV genotype 1 respond . Unknown factor determine difference treatment outcome . Probably virologic immunologic factor play major role . By investigate blood sample HCV / HIV coinfected patient HCV mono-infected patient would like examine virologic immunologic factor possibly responsible difference .</brief_summary>
	<brief_title>Peginterferon Ribavirin Virologic Immunologic Parameters Hepatitis C Mono- Coinfected Patient ( PRIVICOP )</brief_title>
	<detailed_description>background : year Hepatitis C ( HCV ) human immunodeficiency virus ( HIV ) infect worldwide million people . In western world coinfection HIV HCV mainly exist intravenous drug user . In coinfected patient progression liver fibrosis cirrhosis endstage liver disease much fast patient mono-infection hepatitis C. With current treatment regimes response rate differ HCV genotype coinfected mono-infected patient . Reasons yet well understood . Virology : In treatment HCV genotype 1 , 12 week treatment success evaluate ( EVR ) HCV RNA-load insufficiently drop treatment stop . There indication moment evaluation do earlier . Whole blood analysis sensitive method determine earlier EVR.Furthermore known HCV mutation play role chronicity HCV . Lack treatment response cause mutation HCV genome . Sequencing whole HCV genome do extensively . Immunology : Proliferation interferon production HCV specific CD8 cell defective . Not much know HCV-specific CD8 cell responses treatment peginterferon ribavirin . Evidence gather regulatory T-cells ( CD4+CD25+ ) involve process inhibit proliferation . Also know concentration HCV-specific CD4 CD8 cell liver high peripheral blood . Certain home molecule probably involve process . Hypothesis : virologic : 1 ) 4 week possible determine EVR ; 2 ) know , mutation responsible chronicity unresponsiveness HCV virus ; 3 ) whole blood analysis able predict EVR sensitivity current HCV-RNA technique . immunologic : 1 ) specific relation HCV specific CD4 CD8 cell determine proliferation production interferon therapy peginterferon ribavirin successful . 2 ) regulatory T cell inhibit proliferation production chronic HCV infection amount regulatory T cell diminish therapy peginterferon ribavirin . 3 ) wich home molecule important home HCV specific CD8 cell liver .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>All patient treat physician decides start treatment peginterferon ribavirin treatment hepatitis C HCV monoinfection HCV / HIV coinfection Genotype 1 Compliant outpatient visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>virologic</keyword>
	<keyword>immunologic</keyword>
	<keyword>HIV / Hepatitis C coinfection</keyword>
</DOC>